![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
|
Contact: Charlotte Rocker
crocker@gcigroup.com
212-537-8290
GCI Group
Caption: Nexavar (sorafenib) tablets
Credit: Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc.
Usage Restrictions: None
Related news release: Nexavar significantly extends overall survival by 44 percent in liver cancer patients
|